166 related articles for article (PubMed ID: 25401277)
1. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis and potential targets for biologic treatment.
Sanders JS; Abdulahad WH; Stegeman CA; Kallenberg CG
Nephron Clin Pract; 2014; 128(3-4):216-23. PubMed ID: 25401277
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of ANCA-associated vasculitides.
Kallenberg CG
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i59-63. PubMed ID: 21339221
[TBL] [Abstract][Full Text] [Related]
3. Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides.
Lamprecht P; Kerstein A; Klapa S; Schinke S; Karsten CM; Yu X; Ehlers M; Epplen JT; Holl-Ulrich K; Wiech T; Kalies K; Lange T; Laudien M; Laskay T; Gemoll T; Schumacher U; Ullrich S; Busch H; Ibrahim S; Fischer N; Hasselbacher K; Pries R; Petersen F; Weppner G; Manz R; Humrich JY; Nieberding R; Riemekasten G; Müller A
Front Immunol; 2018; 9():680. PubMed ID: 29686675
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
Csernok E; Lamprecht P; Gross WL
Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of ANCA-associated vasculitis: An update.
Jarrot PA; Kaplanski G
Autoimmun Rev; 2016 Jul; 15(7):704-13. PubMed ID: 26970490
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention.
Kallenberg CG; Stegeman CA; Abdulahad WH; Heeringa P
Am J Kidney Dis; 2013 Dec; 62(6):1176-87. PubMed ID: 23810690
[TBL] [Abstract][Full Text] [Related]
7. Complement system activation in ANCA vasculitis: A translational success story?
Kallenberg CG; Heeringa P
Mol Immunol; 2015 Nov; 68(1):53-6. PubMed ID: 26597208
[TBL] [Abstract][Full Text] [Related]
8. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies.
Jennette JC; Falk RJ
Curr Opin Rheumatol; 2008 Jan; 20(1):55-60. PubMed ID: 18281858
[TBL] [Abstract][Full Text] [Related]
9. [Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: advances in pathogenesis and treatment].
Silva F; Cisternas M
Rev Med Chil; 2013 Jun; 141(6):765-73. PubMed ID: 24121580
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of ANCA-associated vasculitis: recent insights from animal models.
van Timmeren MM; Heeringa P
Curr Opin Rheumatol; 2012 Jan; 24(1):8-14. PubMed ID: 22089093
[TBL] [Abstract][Full Text] [Related]
11. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated neutrophil--endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: implications for pathogenesis and disease intervention.
Hu N; Westra J; Kallenberg CG
Autoimmun Rev; 2011 Jul; 10(9):536-43. PubMed ID: 21513817
[TBL] [Abstract][Full Text] [Related]
13. Antineutrophil cytoplasmic antibodies (ANCA): diagnostic utility and potential role in the pathogenesis of vasculitis.
Malenica B; Rudolf M; Kozmar A
Acta Dermatovenerol Croat; 2004; 12(4):294-313. PubMed ID: 15588565
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis-based new perspectives of management of ANCA-associated vasculitis.
Sciascia S; Ponticelli C; Roccatello D
Autoimmun Rev; 2022 Mar; 21(3):103030. PubMed ID: 34971805
[TBL] [Abstract][Full Text] [Related]
15. Review article: Pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Van Timmeren MM; Chen M; Heeringa P
Nephrology (Carlton); 2009 Feb; 14(1):16-25. PubMed ID: 19335841
[TBL] [Abstract][Full Text] [Related]
16. Animal models for anti-neutrophil cytoplasmic antibody-associated vasculitis: Are current models good enough?
Huang F; Lv Y; Liu S; Wu H; Liu Q
Animal Model Exp Med; 2023 Oct; 6(5):452-463. PubMed ID: 37614099
[TBL] [Abstract][Full Text] [Related]
17. ANCA-Associated Vasculitis: Pathogenesis, Models, and Preclinical Testing.
Hutton HL; Holdsworth SR; Kitching AR
Semin Nephrol; 2017 Sep; 37(5):418-435. PubMed ID: 28863790
[TBL] [Abstract][Full Text] [Related]
18. Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model.
McAdoo SP; Prendecki M; Tanna A; Bhatt T; Bhangal G; McDaid J; Masuda ES; Cook HT; Tam FWK; Pusey CD
Kidney Int; 2020 Jun; 97(6):1196-1207. PubMed ID: 32305129
[TBL] [Abstract][Full Text] [Related]
19. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis.
Nakazawa D; Tomaru U; Suzuki A; Masuda S; Hasegawa R; Kobayashi T; Nishio S; Kasahara M; Ishizu A
Arthritis Rheum; 2012 Nov; 64(11):3779-87. PubMed ID: 22777766
[TBL] [Abstract][Full Text] [Related]
20. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
Mohammad AJ; Segelmark M
J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
